GSK Bags Barron As R&D Boss As Vallance Joins UK Government
Executive Summary
UK pharma giant GlaxoSmithKline has nabbed a high-profile figure from Google's Calico to head up its research efforts. Barron's oncology pedigree from his time at Roche suggests that cancer is again a core area for GSK.
You may also be interested in...
New CFO Mackay Completes Top Table At GSK
CEO Emma Walmsley’s plans to transform the leadership at GSK have advanced again with the appointment of HSBC's Iain Mackay as the firm's new chief financial officer.
GSK's Big Reveal: An R&D Overhaul Poised To Yield Long-Term Cultural Change
With few near-term catalysts, GSK's R&D strategy may leave some investors underwhelmed, but President-R&D Hal Barron is focused on making deep cultural and scientific changes at the big pharma. He laid out his initial turnaround plan July 25.
For GSK R&D Head Hal Barron 'There's No Place Like Home' For Seeding Innovation
GSK President R&D Hal Barron came to a big investor meeting with one bit of tangible news, a collaboration with consumer genetics leader 23andMe. Barron and CEO Emma Walmsley talked about the deal and Barron's California headquarters in a media briefing.